Tag: Transdermal

Drug And Gene Delivery Systems Market Worth $786.9 Billion By 2025

The global drug and gene delivery systems market is expected to reach USD 786.9 Billion by 2025, according to a new report by Grand View Research, Inc. Rising investment by the market players to develop innovative drug delivery systems to cater to the demand by the patients as well as to increase the bioavailability at minimum quantity of active pharmaceutical ingredient is driving the market growth. Additionally, increasing focus on R&D of gene delivery systems owing to the high growth potential of gene therapy for the treatment of a wide range of diseases is expected to fuel the market growth in the future.

Drug delivery systems are in a constant evolution along with the changing preference by the patient. For instance, initially, hormone replacement therapy was widely prescribed in the form of pills, whereas, it is now available in the form of prefilled syringes, patches, vaginal rings, gel, and sprays. The principal purpose of development of different forms of delivery systems is to increase the ease of use. Factors such as aesthetics of the delivery systems, price, and amount of API are also considered while designing the drug delivery system.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/drug-gene-delivery-devices-market

Further key findings from the study suggest:

  • The market study suggests that oral segment dominated the market in 2015
  • The convenience of use and low manufacturing cost are the prime factors responsible for the dominance of the oral delivery segment
  • Injectable segment is expected to show a lucrative growth rate owing to the introduction of technically advanced injecting devices that enable convenient self-injection
  • North America dominated the market in 2015 and is expected to remain dominant throughout the forecast period owing to highly developed healthcare infrastructure and high healthcare spending
  • Asia pacific is expected to exhibit the fastest growth rate during the forecast period owing to the factors such as rapidly developing economies, growing disposable income, and high adaption of the advanced delivery systems
  • A few of the major market players in drug delivery systems space are F. Hoffmann-La Roche Ltd, Pfizer, Inc., Johnson and Johnson private Ltd, Novartis AG, Becton, Dickinson and Company, and Bayer AG.
  • Major market players in the gene delivery systems space are SiBiono GeneTech Co., Unique N.V., Epeius Biotechnologies Corporation, Human Stem Cells Institute, and Shanghai Sunway Biotech Co., Ltd.

Hormone Replacement Therapy Market Worth $28.4 Billion By 2022

Global hormone replacement therapy market is expected to reach USD 28.4 billion by 2022, according to a new report by Grand View Research, Inc. Increasing geriatric and neonatal population base, growing cases of hormonal imbalances, and large presence of unmet healthcare needs in emerging economies are some vital impact rendering drivers. 

Estrogen replacement therapy dominated the market in 2015. Moreover, the rising number of women reaching the menopausal age is expected to drive the demand for these treatments over the forecast period. 

Furthermore, rise in premature births that lead to genital disorders and slower rate of growth in these neonates are anticipated to fuel the demand for growth hormone therapy. According to statistics provided by the CDC, over 15 million babies were born preterm in 2014 annually. This number is anticipated to rise over the next seven years and become a leading cause for disabilities, illnesses, arrested development, and mortality. 

To request a sample copy:
http://www.grandviewresearch.com/industry-analysis/hormone-replacement-therapy-market

Further key findings from the study suggest:

  • Estrogen therapy is expected to dominate the product segment and hold over 50.0% of the market share by 2022. This growth can be attributed to the increasing focus of healthcare bodies such as the Women’s Health Initiative, The North America Menopause Society, and The British Menopause Society, on providing safe replacement therapy.
  • The parenteral route of administration is commonly used for delivery of drugs such as Nutropin, Signifor, Genotropin, and Tev-Tropin. Other routes such as pen-based delivery systems and implants are gaining popularity owing to higher patient comfort and ease-of-use. Furthermore, technological advancements in the field providing higher bioavailability of drug and needle-free administration are predicted to positively impact growth.
  • Menopause and their vasomotor symptoms are expected to be the most prevalent disease over the forecast period owing to increasing number of women approaching the menopausal age. The segment is predicted to hold about 40.0% of the market share by 2022.
  • North America, particularly the U.S. dominated the market and held about 35.0% of the total revenue in 2015. Existence of well-regulated healthcare system and presence of a large pool of target population are a few factors that promote growth. Countries such as South Africa, China, India, and Brazil are anticipated to witness lucrative growth over the forecast period, with China predicted to have the fastest growth of over 10.0%.
  • Some key companies catering to hormone replacement therapies include Pfizer, Inc., Merck Serono, Novo Nordisk, Eli Lilly, Bayer Healthcare, Mylan Laboratories, Amgen, Novartis, and Genentech. Introduction of new formulations and development of innovative drug delivery systems are expected to be a few initiatives taken by these players over the forecast period.